A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS

BACKGROUND: Immune checkpoint inhibitors (ICI) PD-1/PD-L1 antibody are key drugs for the treatment of cancer. Bispecific antibody is one of the strategies aimed to meet the clinical needs for cancer patients who are resistant to or refractory from ICI treatment. TIM-3, one of the next generation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Luan, Yan, Deng, Hongyuan, Wang, Fengpo, Wang, Cuihui, Zhang, Zhen, Liu, Xun, Abuduwaili, Kahaerjiang, Liu, Jiajian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370444/
http://dx.doi.org/10.1093/abt/tbad014.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370444/
http://dx.doi.org/10.1093/abt/tbad014.002

Ejemplares similares